SEARCH

SEARCH BY CITATION

References

  • 1
    Eguchi S, Soyama A, Hidaka M, Takatsuki M, Muraoka I, Tomonaga T, et al. Liver transplantation for patients with human immunodeficiency virus and hepatitis C virus coinfection with special reference to hemophiliac recipients in Japan. Surg Today. 2011;41:13251331.
  • 2
    Darby SC, Ewart DW, Giangrande PL, Spooner RG, Rizza CR, Dusheiko GM, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet. 1997;350:14251431.
  • 3
    Merchante N, Merino E, Lopez-Aldeguer J, Jover F, Delgado-Fernandez M, Galindo MJ, et al. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. HIV/AIDS. 2013;56:143150.
  • 4
    Cusinato CT, Koetz AP, Barcellos NT, Wolff FH. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology. 2013;57:249257.
  • 5
    Vispo E, Moreno A, Maida I, Barreiro P, Cuevas A, Albertos S, et al. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS. 2010;24:11711176.
  • 6
    Mendizabal M, Craviotto S, Chen T, Silva MO, Reddy KR. Noncirrhotic portal hypertension: another cause of liver disease in HIV patients. Ann Hepatol. 2009;8:390395.
  • 7
    Kovari H, Ledergerber B, Peter U, Flepp M, Jost J, Schmid P, et al. Swiss HIV Cohort Study. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis. 2009;49:626635.
  • 8
    Merchante N, Girón-González JA, González-Serrano M, Torre-Cisneros J, García-García JA, Arizcorreta A, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS. 2006;20:4957.
  • 9
    Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:16321641.
  • 10
    Ragni MV, Eghtesad B, Schlesinger KW, Dvorchik I, Fung JJ. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl. 2005;11:14251430.
  • 11
    de Vera ME, Dvorchik I, Tom K, Eghtesad B, Thai N, Shakil O, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant. 2006;6:29832993.
  • 12
    Jackson BD, Doyle JS, Hoy JF, Roberts SK, Colman J, Hellard ME, et al. Non-cirrhotic portal hypertension in HIV mono-infected patients. J Gastroenterol Hepatol. 2012;17:15121519.
  • 13
    Murillas J, Rimola A, Laguno M, de Lazzari E, Rascón J, Agüero F, et al. ESLD-HIV Working Group Investigators. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study. Liver Transpl. 2009;15:11331141.
  • 14
    Rullier A, Trimoulet P, Neau D, Bernard PH, Foucher J, Lacoste D, et al. Fibrosis is worse in HIV-HCV patients with low-level immunodepression referred for HCV treatment than in HCV-matched patients. Hum Pathol. 2004;35:10881094.
  • 15
    Ragni MV, Moore CG, Soadwa K, Nalesnik MA, Zajko AB, Cortese-Hassett A, et al. HHH Study Group. Impact of HIV on liver fibrosis in men with hepatitis C infection and haemophilia. Haemophilia. 2011;17:103111.
  • 16
    Resino S, Sánchez-Conde M, Berenguer J. Coinfection by human immunodeficiency virus and hepatitis C virus: noninvasive assessment and staging of fibrosis. Curr Opin Infect Dis. 2012;25:564569.
  • 17
    Merchante N, Rivero-Juárez A, Téllez F, Merino D, José Ríos-Villegas M, Márquez-Solero M, et al. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Hepatology. 2012;56:228238.
  • 18
    Miro JM, Torre-Cisnero J, Moreno A, Tuset M, Quereda C, Laguno M, et al. [GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005)]. Enferm Infecc Microbiol Clin. 2005;23:353362.
  • 19
    O'Grady J, Taylor C, Brook G. Guidelines for liver transplantation in patients with HIV infection (2005). HIV Med. 2005;6(Suppl 2):149153.
  • 20
    Xia XJ, Liu BC, Su JS, Pei H, Chen H, Li L, et al. Preoperative CD4 count or CD4/CD8 ratio as a useful indicator for postoperative sepsis in HIV-infected patients undergoing abdominal operations. J Surg Res. 2012;174:e2530.
  • 21
    Takatsuki M, Eguchi S, Soyama A, Kanematsu T, Nakao K, Shirasaka T, et al. Evaluation of portal hypertension and prognosis of patients with HIV-HCV co-infection through comtaminated blood product. Acta Hepatol Japonica (KANZO). 2012;53:586590 (in Japanese).
  • 22
    Soyama A, Eguchi S, Takatsuki T, Hidaka M, Muraoka I, Kanematsu T. Analysis of hepatic functional reserve in HIV_HCV co-infected patients. Acta Hepatol Japonica (KANZO). 2012;53:403408 (in Japanese).
  • 23
    López-Diéguez M, Montes ML, Pascual-Pareja JF, Quereda C, Von Wichmann MA, Berenguer J, et al. GESIDA 37/03-FIPSE 36465/03-NEAT IG5 Study Group. The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS. 2011;25:899904.
  • 24
    Schreibman I, Gaynor JJ, Jayaweera D, Pyrsopoulos N, Weppler D, Tzakis A, et al. Outcomes after orthotopic liver transplantation in 15 HIV-infected patients. Transplantation. 2007;84:697705.
  • 25
    Duclos-Vallee JC, Feray C, Sebagh M, Sebagh M, Teicher E, Roque-Afonso AM, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2008;47:407417.
  • 26
    Miro JM, Montejo M, Castells L, Rafecas A, Moreno S, Agüero F, et al. Spanish OLT in HIV-Infected Patients Working Group investigators. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant. 2012;12:18661876.
  • 27
    Anadol E, Beckebaum S, Radecke K, Paul A, Zoufaly A, Bickel M, et al. Orthotopic liver transplantation in human-immunodeficiency-virus-positive patients in Germany. AIDS Res Treat. 2012;2012:49.
  • 28
    Harbell J, Fung J, Nissen N, Olthoff K, Florman SS, Hanto DW, et al. Surgical complication in 275 HIV-infected liver and/or kidney transplantation recipients. Surgery. 2012;152:376381.
  • 29
    Ragni MV, Devera ME, Roland ME, Wong M, Stosor V, Sherman KE, et al. Liver transplant outcomes in HIV(+) haemophilic men. Haemophilia. 2013;19:134140.
  • 30
    O'Grady JG. Liver transplantation in human immunodeficiency virus/hepatitis C virus-coinfected patients: response needed! Liver Transpl. 2012;18:617618.
  • 31
    Baccarani U, Adani GL, Bragantini F, Londero A, Comuzzi C, Rossetto A, et al. Long-term outcomes of orthotopic liver transplantation in human immunodeficiency virus-infected patients and comparison with human immunodeficiency virus-negative cases. Transplant Proc. 2011;43:11191122.
  • 32
    Tsukada K, Sugawara Y, Kaneko J, Tamura S, Tachikawa N, Morisawa Y, et al. Living donor liver transplantations in HIV- and hepatitis C virus-coinfected hemophiliacs: experience in a single center. Transplantation. 2011;91:12611264.
  • 33
    Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, et al. Solid Organ Transplantation in HIV: Multi-Site Study Investigators. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012;18:716726.
  • 34
    García F, Plana M, Vidal C, Cruceta A, O'Brien WA, Pantaleo G, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS. 1999;13:F7986.
  • 35
    Neff GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl. 2003;9:239247.
  • 36
    Castells L, Escartín A, Bilbao I, Len O, Allende H, Vargas V, et al. Liver transplantation in HIV-HCV coinfected patients: a case-control study. Transplantation. 2007;83:354358.
  • 37
    Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant. 2007;7:28162820.
  • 38
    Armstrong MJ, Corbett C, Rowe IA, Taylor GP, Neuberger JM. HTLV-1 in solid-organ transplantation: current challenges and future management strategies. Transplantation. 2012;94:10751084.
  • 39
    Tricot L, Teicher E, Peytavin G, Conti F, Calmus Y, Barrou B, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant. 2009;9:19461952.
  • 40
    Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis. 2001;183:11121115.
  • 41
    Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013;159:8696.
  • 42
    Polard E, Camus C, Abault AY, Turlin B, Arvieux C, Messner M, et al. Retransplantation for acute liver failure due to combined antiviral agents in an HIV-HCV coinfected liver transplant recipient. Transplantation. 2005;80:11361138.
  • 43
    Lin YL, Mettling C, Portales P, Reynes J, Clot J, Corbeau P. Cell surface CCR5 density determines the post-entry efficiency of R5 HIV-1 infection. Proc Natl Acad Sci U S A. 2002;99:1559015595.
  • 44
    Weissman D, Dybul M, Daucher MB, Davey RT Jr, Walker RE, Kovacs JA. Interleukin-2 up-regulates expression of the human immunodeficiency virus fusion coreceptor CCR5 by CD4+ lymphocytes in vivo. J Infect Dis. 2000;181:933938.
  • 45
    Heredia A, Amoroso A, Davis C, Le N, Reardon E, Dominique JK, et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci U S A. 2003;100:1041110416.
  • 46
    Di Benedetto F, Di Sandro S, De Ruvo N, Montalti R, Ballarin R, Guerrini GP, et al. First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation. Transplantation. 2010;89:733738.
  • 47
    Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, et al. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011;17:13941403.
  • 48
    Marubashi S, Umeshita K, Asahara T, Fujiwara K, Haga H, Hashimoto T, et al. Steroid-free living donor liver transplantation for HCV – a multicenter prospective cohort study in Japan. Clin Transplant. 2012;26:857867.
  • 49
    Di Benedetto F, Tarantino G, Ercolani G, Baccarani U, Montalti R, De Ruvo N, et al. Multicenter Italian experience in liver transplantation for hepatocellular carcinoma in HIV-infected patients. Oncologist. 2013;18:592599.
  • 50
    Baccarani U, Adani GL, Tavio M, Viale P. Liver transplantation for hepatocellular carcinoma: the impact of human immunodeficiency virus infection. Hepatology. 2011;53:21382139.